INTRODUCTION 30
Human β-defensins (hBD) are cationic antimicrobial peptides produced predominantly 31 by epithelial cells (1) . Notably in the intestine, an environment populated by a dense and rich 32 microbial community, epithelial defensins reinforce the host innate defense (2). These 33 peptides are normally expressed at low basal levels, but hBD-2 and -3 can be upregulated by a 34 variety of microbial and inflammatory stimuli (3, 4). In particular, altered hBD-2 expression 35 has been reported to correlate with the development of intestinal inflammation (5, 6). On the 36 other hand, intestinal inflammation has been associated with alterations in the microbiota, for 37 example, shifts in the relative abundance of Proteobacteria such as Escherichia coli (7, 8) . 38
Elucidating how the interaction between hBD and its bacterial targets impact inflammatory 39 processes can aid our understanding of the host-microbial networking in health and disease. 40
The most studied mechanism of action of cationic antimicrobial peptides involves 41 membrane permeabilization with eventual cell lysis; however, other mechanisms and cellular 42 targets are described for many peptides including human defensins (9-12). Moreover, 43 alongside their antimicrobial activity, manifold immunomodulatory properties of defensins 44 are reported, many of which describe direct effects upon immune cells and cytokine 45 expression (13-15). In some cases, the interaction of peptides with bacterial components is 46 implicated in their immunomodulatory effects (16, 17) . In this context, the present study 47 hypothesized if hBD-2 activity upon E. coli could result in the generation of extracellular 48 mediators with relevance for immunomodulation. 49
MATERIALS AND METHODS 50
Chemicals. Lyophilized synthetic human beta-defensin-2, human beta-defensin-3 and 51 human alfa-defensin-5 were purchased from Peptide Institute Inc., Sheep Myeloid 52 Antimicrobial Peptide 29 (SMAP29) from AnaSpec Inc. and magainin I from Sigma-Aldrich. 53
Adenosine (Ado), guanosine (Guo), cytidine (Ctd) and uridine (Urd), as well as their 54 corresponding monophosphates and nitrogen bases were purchased from Sigma-Aldrich. for transmission electron microscopy (TEM), as described previously (18). 101
Isotopic labeling experiments. Isotopic labeling and determination of isotopic ratio 102
were performed to elucidate the origin of defensin-induced extracellular compounds. Bacteria 103 were labeled by the addition of 0.5 g/l [U-
13 C]-glucose (99 % 13 C) ( 13 C 6 -Glu; Euriso-Top) to 104 the culture medium. Total DNA and RNA were extracted and purified from cultures 105 immediately before defensin treatment, using commercial kits (Qiagen) and subsequently 106 degraded according to a standard enzymatic protocol (19) . Products were lyophilized and 107 incubated with trimethilsilylation reagent: pyridine (4:1) for 1 h at 100 ºC for derivatization. 1C) were then compared to a web-based data repository (22) and to commercially 125 available standards, and the compounds in peaks #1 and #2 were identified as the purine 126 nucleosides adenosine (Ado) and guanosine (Guo), respectively. 127 on October 2, 2017 by guest http://aac.asm.org/
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Quantitative characterization (Fig. 2) showed that the treatment of logarithmic E. coli 128 cultures with hBD-2 resulted in the presence of extracellular nucleosides at low-μM range, 129 detected exclusively after peptide addition and not in untreated controls. The variation over 130 time after hBD-2 treatment highlighted differences in the temporal dynamics, the 131 accumulation of Ado being accentuated at longer time-points (Fig. 2A) . The dose-response 132 curve ( Fig. 2B and 2C ) demonstrated that below 10 μg/ml hBD-2 was not able to induce 133 accumulation of the compounds; towards higher doses, the concentration of both compounds 134 increased. Ado was more abundant than Guo at intermediate doses (20 -30 μg/ml). On the 135 other hand, the response also varied according to cell density, the concentration of Ado being 136 higher than Guo when cultures were treated at higher OD values ( Fig. 2D and 2E ). The 137 growth-curves corresponding to the dose-response and the density-response experiments ( 
Different antimicrobial peptides have contrasting abilities to induce extracellular 144
adenosine in E. coli. In addition to hBD-2, two other human defensins were tested (human β-145 defensin-3 and human α-defensin-5) and two non-human peptides (SMAP and magainin I) 146
were also analyzed as a comparison. At the dose of 20 µg/ml, all peptides were equally able to 147 arrest bacterial growth in liquid cultures (data not shown). In contrast, the extracellular 148 concentration of Ado generated by the bacteria after treatment was remarkably different for 149 each peptide, being hBD-2 the most efficient to elicit this response (Table 1 ). In another 150 comparative approach, the accumulation of extracellular Ado in response to hBD-2 was 151 evaluated in a different strain, the probiotic E. coli Nissle 1917, using identical conditions as 152 specified for E. coli strain W. The treatment of the probiotic strain with hBD-2 (20 µg/ml) 153 also resulted in the presence of extracellular Ado (0.632 ± 0.009 µM) 2 h after peptide 154 addition 155
Adenosine accumulation did not result from plain cell lysis. Next, bacterial viability 156 and membrane integrity were investigated in the defensin-treated cultures, to evaluate the 157 occurrence of peptide-mediated lysis. Bacterial growth was arrested after treatment with hBD-158 2 at 20 μg/ml (Fig. 3A) ; accordingly, metabolic activity was also immediately impaired and 159 CFU counts showed that the cultures were no longer viable shortly after addition of hBD-2 160 (Fig. 3B) . The release of intracellular molecules into the medium was examined as an 161 on October 2, 2017 by guest http://aac.asm.org/ Downloaded from indication of lysis (Fig. 3C) . Like untreated controls, hBD-2 did not result in the release of 162 ATP, DNA, nor proteins. Fluorescence microscopy confirmed that intracellular material was 163 kept within discrete cells in hBD-2-treated bacteria, in contrast to cultures subjected to freeze-164 thaw lysis. Importantly, extracellular Ado levels were not significantly increased following 165 lysis protocol. These results indicated that although cellular processes were severely affected 166 by hBD-2, intracellular contents were not indiscriminately released in the extracellular 167 medium. 168
Structural evidence was obtained by transmission electron microscopy (TEM). 169
Untreated E. coli cells (Fig. 3D, left column) showed intact membranes and cytoplasm 170 organization and the presence of small areas of plasmolysis was observed only in few cells 171 (8%). In contrast, in hBD-2-treated cultures (Fig. 3D, right containing medium were treated with hBD-2 (20 μg/ml). The isotopic ratio of extracellular 179
Ado was compared to that of nucleic acids extracted immediately before treatment and was 180 found to be in the same range as the pre-existent RNA in labeled cultures (Fig. 4A) . Targeted 181 tandem-MS (Fig. 4B ) demonstrated that ribonucleotides and pyrimidine nucleosides were also 182 present in the supernatants of treated cultures, supporting the conclusion that extracellular 183
Ado derived from bacterial RNA. In contrast, deoxyribose compounds were not detected. 184
Interestingly, addition of total RNA purified from E. coli increased Ado concentration 185 detected after hBD-2 treatment (Fig. 4C) We are grateful to Esther Surges and Ina Schleicher for technical assistance. 274 Table  402   Table 1 
